Failed Eradication Therapy of New-Onset Pseudomonas aeruginosa Infections in Children With Cystic Fibrosis Is Associated With Bacterial Resistance to Neutrophil Functions
- PMID: 33606875
- PMCID: PMC9159338
- DOI: 10.1093/infdis/jiab102
Failed Eradication Therapy of New-Onset Pseudomonas aeruginosa Infections in Children With Cystic Fibrosis Is Associated With Bacterial Resistance to Neutrophil Functions
Abstract
Background: Antibiotics, such as inhaled tobramycin, are used to eradicate new-onset Pseudomonas aeruginosa (PA) infections in patients with cystic fibrosis (CF) but frequently fail due to reasons poorly understood. We hypothesized that PA isolates' resistance to neutrophil antibacterial functions was associated with failed eradication in patients harboring those strains.
Methods: We analyzed all PA isolates from a cohort of 39 CF children with new-onset PA infections undergoing tobramycin eradication therapy, where 30 patients had eradicated and 9 patients had persistent infection. We characterized several bacterial phenotypes and measured the isolates' susceptibility to neutrophil antibacterial functions using in vitro assays of phagocytosis and intracellular bacterial killing.
Results: PA isolates from persistent infections were more resistant to neutrophil functions, with lower phagocytosis and intracellular bacterial killing compared to those from eradicated infections. In multivariable analyses, in vitro neutrophil responses were positively associated with twitching motility, and negatively with mucoidy. In vitro neutrophil phagocytosis was a predictor of persistent infection following tobramycin even after adjustment for clinical risk factors.
Conclusions: PA isolates from new-onset CF infection show strain-specific susceptibility to neutrophil antibacterial functions, and infection with PA isolates resistant to neutrophil phagocytosis is an independent risk factor for failed tobramycin eradication.
Keywords: Pseudomonas aeruginosa; antibiotic eradication therapy; cystic fibrosis; neutrophil phagocytosis.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures


Similar articles
-
Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.Eur J Clin Microbiol Infect Dis. 2016 Jan;35(1):67-74. doi: 10.1007/s10096-015-2509-4. Eur J Clin Microbiol Infect Dis. 2016. PMID: 26492874
-
Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.Health Technol Assess. 2021 Nov;25(65):1-128. doi: 10.3310/hta25650. Health Technol Assess. 2021. PMID: 34806975 Clinical Trial.
-
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.Microbiol Spectr. 2022 Dec 21;10(6):e0184222. doi: 10.1128/spectrum.01842-22. Epub 2022 Dec 1. Microbiol Spectr. 2022. PMID: 36453898 Free PMC article.
-
Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.Cochrane Database Syst Rev. 2019 Dec 17;12(12):CD012300. doi: 10.1002/14651858.CD012300.pub2. Cochrane Database Syst Rev. 2019. PMID: 31845758 Free PMC article.
-
Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.Drugs. 2003;63(22):2501-20. doi: 10.2165/00003495-200363220-00015. Drugs. 2003. PMID: 14609360 Review.
Cited by
-
Utilizing in silico and in vitro methods to identify possible binding sites of a novel ligand against Pseudomonas aeruginosa phospholipase toxin ExoU.Biochem Biophys Rep. 2021 Dec 16;29:101188. doi: 10.1016/j.bbrep.2021.101188. eCollection 2022 Mar. Biochem Biophys Rep. 2021. PMID: 34984240 Free PMC article.
-
Therapeutic Interventions for Pseudomonas Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials.J Clin Med. 2024 Oct 30;13(21):6530. doi: 10.3390/jcm13216530. J Clin Med. 2024. PMID: 39518670 Free PMC article. Review.
-
Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle.Adv Sci (Weinh). 2023 Feb;10(5):e2204443. doi: 10.1002/advs.202204443. Epub 2023 Jan 3. Adv Sci (Weinh). 2023. PMID: 36596691 Free PMC article.
References
-
- Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918–51. - PubMed
-
- Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. ; Early Pseudomonas Infection Control (EPIC) Investigators . Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165:847–56. - PMC - PubMed
-
- Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. J Cyst Fibros 2014; 13:172–8. - PubMed
-
- Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group . Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65:286–91. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical